Breaks Categories: News

ThursdayMay 16, 2024 10:55 am

NetworkNewsBreaks – Splash Beverage Group Inc. (NYSE American: SBEV) CEO Shares Shareholder Letter, Corporate Update

Splash Beverage (NYSE American: SBEV), a portfolio company of leading beverage brands, and its chair and CEO Robert Nistico have released a letter to shareholders. In the letter, Nistico shared information from the company’s first-quarter 2024 results, along with a corporate update. Notable numbers from the quarter include sales of $1.2 million from the company’s branded beverage division, down from $1.9 million over the same period last year, with the company’s eCommerce division, Qplash, reporting shipments “well below” demand and capabilities. Nistico provided an explanation for the lower numbers, noting that the company reports revenue from shipments to distributors, which typically maintain…

Continue Reading

WednesdayMay 15, 2024 2:51 pm

NetworkNewsBreaks – Emperor Metals Inc. (CSE: AUOZ) (OTCQB: EMAUF) (FRA: 9NH) Featured in Couloir Capital Report with ‘Buy’ Recommendation

Emperor Metals (CSE: AUOZ) (OTCQB: EMAUF) (FRA: 9NH), an advanced-stage, gold-exploration company focused on proving and developing the substantial resource potential of its flagship Duquesne West Gold Project, is spotlighted in a recent Couloir Capital Report. Couloir Capital is a research-driven investment dealer focused on emerging companies in the natural-resources sector. The report recommends Emperor Metals as a Buy with high risk and an initial fair market value target of $0.72. The report notes several investment highlights, including the company’s focus on expanding resource on the project through 3D modeling of resource targets and successful drilling programs and its option to acquire…

Continue Reading

WednesdayMay 15, 2024 2:22 pm

NetworkNewsBreaks – EF Hutton Collaborates with IBN to Provide Coverage, Elevate Visibility of Annual Global Conference

EF Hutton, a fast-paced, high-growth investment bank founded by experienced investment professionals, is working with IBN (“InvestorBrandNetwork”), a cutting-edge corporate communications firm and content distributor; IBN is an official media sponsor for today’s EF Hutton Annual Global Conference in New York City. As a media sponsor, IBN has focused on elevating the visibility of today’s event through amplified article syndication as well as an array of digital solutions designed increase recognition of participating companies and conference sponsors. As part of those efforts, IBN provided its audiences with summaries on each participating company and issued a special conference-focused email broadcast to subscribers of…

Continue Reading

WednesdayMay 15, 2024 2:21 pm

NetworkNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Announces Q1 2024 Results, Renews Agreement with the University of Southern California to Advance Annealing Quantum Computing Research and Adoption

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, has announced financial results for its first fiscal quarter ended March 31, 2024. Q1 revenues were up more than 50% year over year and Q1 gross profit surged 294% year over year. “We believe D-Wave’s first quarter revenue and bookings reflect growing customer demand for quantum and hybrid quantum solutions that can drive measurable impact today,” said Dr. Alan Baratz, CEO of D-Wave. “Coupled with the significant technical milestones we’ve achieved with the Advantage2™ prototype, we believe our progress leading the commercialization of quantum is…

Continue Reading

WednesdayMay 15, 2024 1:52 pm

NetworkNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces Q1 2024 Financial Results

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, today announced financial results for the first quarter ended March 31, 2024. During the quarter, the company reported a loss from operations of $629,972, as compared to an operating loss of $521,258 for the comparable period in 2023. Sigyn Therapeutics’ net loss for Q1 2024 was $758,088 or $0.62 per share, as compared to a net loss of $1,341,036, or $1.39 per share, during Q1 2023. During the first quarter, SIGY completed a 1-for-40 reverse split of its common stock. As a result, 1,224,827 shares of company’s common stock are currently…

Continue Reading

WednesdayMay 15, 2024 1:36 pm

NetworkNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Announces Record Consolidated Q1 2024 Revenues, Improved Quarterly Margins

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced record financial results for the first fiscal quarter ended March 31, 2024, which includes the consolidation of the operations of its e-commerce business with the results of its healthcare operations, Progressive Care Inc. (OTCQB: RXMD). “First quarter results continued to demonstrate the fundamental strength of NextPlat’s focus on the large healthcare services and global e-commerce technology markets and further demonstrates our team execution against its global growth plans,” said Charles M. Fernandez, executive chairman and CEO of NextPlat Corp. “Throughout the remainder of 2024, we are committed to maximizing and…

Continue Reading

WednesdayMay 15, 2024 1:23 pm

NetworkNewsBreaks – PaxMedica Inc. (PXMD) Appeals NASDAQ Delisting Decision, Prepares for June FDA Meeting

PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has filed a formal notice of appeal with the NASDAQ Office of Appeals and Review; the company is appealing to reverse the decision of the NASDAQ Hearings Panel to delist the company from. The company also announced that it has retained Jacob Frenkel, Dickinson Wright, PLLC as its lead counsel in the appeal. According to the announcement, PaxMedica believes the hearings panel did not sufficiently or appropriately consider crucial aspects of the company’s recent achievements and ongoing actions to regain compliance. “We are seeking a reevaluation of…

Continue Reading

WednesdayMay 15, 2024 12:34 pm

NetworkNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Releases Q2 2024 Financial, Business Result; Announces Expansion of Commercial EV Dealer Network

  Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, is reporting on the financial results and business highlights for the three and six months ended March 31, 2024. Key achievements during the quarter include receiving approval from the U.S. Department of Commerce for Foreign Trade Zone status at its Tunica, Mississippi, commercial vehicle manufacturing facility; adding national and regional fleet focus in the Midwest and West Coast and expanding its retail commercial dealer network with the addition of Pritchard EVs and National Auto Fleet Group; and receiving California Air Resource Board’s (“CARB”) HVIP approval for the Mullen THREE, Class…

Continue Reading

WednesdayMay 15, 2024 10:49 am

NetworkNewsBreaks – Correlate Energy Corp. (CIPI), Energetic Capital Collaborate to Unlock Large Untapped Market

Correlate (OTCQB: CIPI) today announced a shared projects pipeline initiative with Energetic Capital aimed at delivering renewable and distributed energy resources into underserved communities. The companies will combine forces to leverage Energetic Capital’s innovative financing structure coupled with Correlate Energy’s proficiency in renewable energy project development. The move ensures efficient access to initiatives like the EPA Greenhouse Gas Reduction Fund (“GGRF”), enabling the seamless execution of renewable energy projects. “Our mission is to make sure distributed energy is fairly distributed,” said Jeff McAulay, CEO of Energetic Capital. “Correlate is one of the industry leaders in delivering distributed energy solutions to…

Continue Reading

WednesdayMay 15, 2024 9:00 am

NetworkNewsBreaks – TC BioPharm (Holdings) PLC (NASDAQ: TCBP) Initiates Compassionate Use Program in the UK Expanding Access to TCB008

TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that TCB008, its lead therapeutic, will be available to patients through a newly launched compassionate use program in the U.K. The announcement noted that this program will provide medical practitioners with treatment options for patients who are ineligible to access experimental treatments through ongoing clinical studies and those whose clinical needs cannot currently be met with licensed treatments. “In addition to helping patients, this step will increase our data set and knowledge around TCB-008 and inform a broader…

Continue Reading